| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Incyte Corporation (NASDAQ: INCY)
INCY Technical Analysis
5
| As on 9th Jun 2023 INCY STOCK Price closed @ 61.04 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 74.05 & Strong Sell for SHORT-TERM with Stoploss of 71.80 we also expect STOCK to react on Following IMPORTANT LEVELS. |
INCYSTOCK Price
| Open | 61.34 | Change | Price | % |
| High | 61.76 | 1 Day | -0.47 | -0.76 |
| Low | 60.73 | 1 Week | -0.51 | -0.83 |
| Close | 61.04 | 1 Month | -12.61 | -17.12 |
| Volume | 1493279 | 1 Year | -12.64 | -17.16 |
| 52 Week High 86.01 | 52 Week Low 61.39 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| INCY Daily Charts |
INCY Intraday Charts |
Whats New @ Bazaartrend |
INCY Free Analysis |
|
|
INCY Important Levels Intraday
| RESISTANCE | 63.02 |
| RESISTANCE | 62.39 |
| RESISTANCE | 61.99 |
| RESISTANCE | 61.60 |
| SUPPORT | 60.48 |
| SUPPORT | 60.09 |
| SUPPORT | 59.69 |
| SUPPORT | 59.06 |
INCY Forecast May 2024
| 4th UP Forecast | 82.03 |
| 3rd UP Forecast | 75.3 |
| 2nd UP Forecast | 71.14 |
| 1st UP Forecast | 66.98 |
| 1st DOWN Forecast | 55.1 |
| 2nd DOWN Forecast | 50.94 |
| 3rd DOWN Forecast | 46.78 |
| 4th DOWN Forecast | 40.05 |
INCY Weekly Forecast
| 4th UP Forecast | 69.94 |
| 3rd UP Forecast | 67.09 |
| 2nd UP Forecast | 65.32 |
| 1st UP Forecast | 63.56 |
| 1st DOWN Forecast | 58.52 |
| 2nd DOWN Forecast | 56.76 |
| 3rd DOWN Forecast | 54.99 |
| 4th DOWN Forecast | 52.14 |
INCY Forecast2024
| 4th UP Forecast | 110.33 |
| 3rd UP Forecast | 94.52 |
| 2nd UP Forecast | 84.75 |
| 1st UP Forecast | 74.98 |
| 1st DOWN Forecast | 47.1 |
| 2nd DOWN Forecast | 37.33 |
| 3rd DOWN Forecast | 27.56 |
| 4th DOWN Forecast | 11.75 |
Incyte Corporation ( NASDAQ USA Symbol : INCY )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
INCY Business Profile
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. Address: 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service